[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Bispo Júnior RZ, Camargo OP: Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paulo); 2009;64(12):1177-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy.
  • Discovery of such prognostic factors would permit selection of a subgroup of at-risk patients, with the aim of improving the therapeutic effectiveness.
  • OBJECTIVE: To identify prognostic factors related to local recurrence-free survival, metastasis-free survival and overall survival among patients with highly malignant primary osteosarcoma that was non-metastatic on diagnosis and had poor response to neoadjuvant chemotherapy.
  • RESULTS: The adverse factors that influenced the risk of local recurrence and the overall survival in univariate analysis were histological subtype other than osteoblastic (p = 0.017) and tumor size greater than 15 cm (p = 0.048).
  • CONCLUSIONS: Tumor size greater than 15 cm is an adverse factor for local recurrence-free survival and overall survival but did not influence metastasis-free survival.
  • The osteosarcoma histological type is a significant independent predictor for local recurrence-free survival, metastasis-free survival and overall survival.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Epidemiologic Methods. Female. Humans. Male. Neoadjuvant Therapy. Prognosis. Risk Factors. Treatment Failure. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4016-27 [11118462.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1145-50 [11583198.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jan;24(1):27-30 [11902735.001]
  • [Cites] Eur J Cancer. 2002 Jun;38(9):1218-25 [12044509.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):3068-75 [12784343.001]
  • [Cites] J Pediatr (Rio J). 2004 Jan-Feb;80(1):65-70 [14978552.001]
  • [Cites] J Bone Joint Surg Am. 1967 Jan;49(1):101-10 [5225072.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):14-8 [299812.001]
  • [Cites] Cancer Treat Rep. 1978 Feb;62(2):193-7 [273474.001]
  • [Cites] Cancer. 1979 Jun;43(6):2163-77 [88251.001]
  • [Cites] J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 [7000786.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1178-84 [3476688.001]
  • [Cites] Semin Diagn Pathol. 1987 Aug;4(3):212-36 [3313606.001]
  • [Cites] J Bone Joint Surg Am. 1990 Jun;72(5):643-53 [2355025.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1988-97 [2230890.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):82-5 [2249566.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):733-7 [1855172.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):60-6 [1884560.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):5-15 [1370176.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):698-708 [1730120.001]
  • [Cites] Int Orthop. 1992;16(1):55-8 [1572772.001]
  • [Cites] Orthopedics. 1992 May;15(5):599-604 [1589352.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1579-91 [1403038.001]
  • [Cites] Int J Cancer. 1993 Aug 19;55(1):44-50 [8344751.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3227-38 [8242546.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):423-31 [8113851.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):203-10 [8000997.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):848-58 [8622033.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] Acta Orthop Scand Suppl. 1997 Feb;273:156-60 [9057608.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):911-7 [9314869.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1161-8 [16505436.001]
  • [Cites] Clinics (Sao Paulo). 2006 Apr;61(2):99-106 [16680325.001]
  • [Cites] Clinics (Sao Paulo). 2006 Oct;61(5):381-6 [17072434.001]
  • [Cites] Clinics (Sao Paulo). 2008 Apr;63(2):157-64 [18438568.001]
  • [Cites] Eur J Cancer. 2009 Sep;45(13):2367-75 [19349163.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):32-8 [11165127.001]
  • (PMID = 20037705.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC2797586
  • [Keywords] NOTNLM ; Bone neoplasms / Drug therapy / Epidemiology / Pathology / Surgery
  •  go-up   go-down


2. Natarajan M, Paraskumar M, Rajkumar G, Sivaseelam A, Natarajan S: Limb salvage in aggressive and malignant tumours of the fibula. Int Orthop; 2004 Oct;28(5):307-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage in aggressive and malignant tumours of the fibula.
  • We treated 25 patients with aggressive and malignant fibular tumours between April 1989 and May 2001.
  • Neo-adjuvant and adjuvant chemotherapy were given to all patients with osteosarcoma and Ewing's sarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / surgery. Limb Salvage. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Chondrosarcoma / mortality. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Osteosarcoma / mortality. Osteosarcoma / pathology. Osteosarcoma / surgery. Retrospective Studies. Risk Assessment. Sarcoma, Ewing / mortality. Sarcoma, Ewing / pathology. Sarcoma, Ewing / surgery. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1977 Jun;(125):173-6 [267531.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):306-10 [6363419.001]
  • [Cites] Clin Orthop Relat Res. 1984 Jun;(186):172-81 [6723139.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] Acta Orthop Scand. 1986 Aug;57(4):290-4 [3538754.001]
  • [Cites] J Bone Joint Surg Br. 1994 Jul;76(4):559-62 [8027140.001]
  • [Cites] Orthop Clin North Am. 1989 Jul;20(3):487-503 [2662118.001]
  • [Cites] J Bone Joint Surg Am. 1991 Apr;73(4):575-83 [2013596.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jun;(279):223-8 [1600659.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Am. 1988 Feb;70(2):307-10 [3277972.001]
  • (PMID = 15338200.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3456982
  •  go-up   go-down


3. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D: Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene; 2009 Nov 5;28(44):3866-79
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
  • Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by malignant plasma cells.
  • Given the frequently long time span from diagnosis of early-stage plasma cell dyscrasias to overt myeloma and the mostly low proliferation rate of malignant plasma cells, we hypothesize these to similarly express a novel class of inhibitory factors of potential prognostic relevance.
  • BMP6 is the only BMP expressed by malignant and normal plasma cells.
  • A high BMP6 expression in primary myeloma cell samples delineates significantly superior overall survival for patients undergoing high-dose chemotherapy independent of conventional prognostic factors (International Staging System (ISS) stage, beta(2) microglobulin).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Bone Morphogenetic Protein 6 / biosynthesis. Cell Proliferation. Gene Expression Regulation, Neoplastic. Multiple Myeloma / metabolism. Multiple Myeloma / mortality. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / mortality


Advertisement
4. Weber K, Damron TA, Frassica FJ, Sim FH: Malignant bone tumors. Instr Course Lect; 2008;57:673-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant bone tumors.
  • Malignant bone tumors represent a small percentage of cancers nationwide and also are much less common than malignant soft-tissue tumors.
  • The rarity of the condition makes it imperative that orthopaedic surgeons in nononcologic practices are able to recognize the symptoms that suggest a possible bony malignancy to avoid inappropriate or delayed treatment.
  • The most common primary malignant bone tumors, osteosarcoma and Ewing's sarcoma, occur in childhood.
  • The primary symptom of a patient with a malignant bone tumor is pain, which often occurs at rest or at night.
  • There are also characteristic findings on physical examination such as swelling or decreased joint range of motion.
  • Patients with a likely malignancy require thorough staging to determine the extent of disease and a well-planned biopsy for accurate diagnosis.
  • Knowledge of specific tumor characteristics and treatment options for osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, chordoma, and adamantinoma is important.
  • Patients with osteosarcoma and resectable Ewing's sarcoma are treated with chemotherapy followed by surgical resection.
  • Secondary sarcomas can occur in previously benign bone lesions and require aggressive treatment.
  • Specific techniques are available for the resection of malignant bone tumors from the upper extremities, lower extremities, pelvis, and spine.
  • The care of patients with primary malignant bone tumors requires a multidisciplinary approach to treatment.
  • [MeSH-minor] Global Health. Humans. Morbidity. Neoplasm Staging / methods. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399615.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


5. Szende B, Horváth A, Bökönyi G, Kéri G: Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. Br J Cancer; 2003 Jan 13;88(1):132-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
  • A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide.
  • Antimetastatic effect of TT-232 treatment combined with DTIC was studied using the B16 mouse melanoma muscle - lung metastasis model.
  • Nearly 50% growth inhibition of HT-58 lymphoma was achieved by daily treatment with 1 mg kg(-1) TT-232.
  • The combination of 1 mg kg(-1) TT-232 and 5 mg kg(-1) etoposide was significantly more effective than TT-232 or etoposide as a single treatment.
  • These experimental data suggest that TT-232 may be an effective new tool in the combination chemotherapy of malignant tumours like melanoma and lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Melanoma, Experimental / drug therapy. Neoplasms, Experimental / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Animals. Dacarbazine / therapeutic use. Disease Models, Animal. Drug Therapy, Combination. Etoposide / therapeutic use. Humans. Lymphoma / drug therapy. Male. Mice. Mice, Inbred CBA. Neoplasm Metastasis. Neoplasm Transplantation. Peptides, Cyclic / therapeutic use. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] Endocrine. 1999 Feb;10(1):25-34 [10403568.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):3265-8 [10652622.001]
  • [Cites] Eur J Nucl Med. 2000 Apr;27(4):447-58 [10805119.001]
  • [Cites] Plast Reconstr Surg. 2000 Apr;105(5):1774-99; quiz 1800-1 [10809113.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):1023-7 [10810391.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):412-8 [10975547.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 3;93(1):22-30 [11136838.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):71-5 [11299792.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 13;285(2):483-8 [11444868.001]
  • [Cites] J Pept Res. 2001 Aug;58(2):91-107 [11532069.001]
  • [Cites] Cell Signal. 2001 Oct;13(10):717-25 [11602182.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 2;288(3):564-72 [11676480.001]
  • [Cites] Cancer. 1981 Oct 1;48(7):1668-73 [7284966.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1566-70 [2880660.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):6977-85 [2903792.001]
  • [Cites] Anticancer Res. 1991 Jul-Aug;11(4):1645-9 [1720940.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Mar 15;191(2):681-7 [8096383.001]
  • [Cites] Pept Res. 1993 Sep-Oct;6(5):281-8 [7903057.001]
  • [Cites] Int J Pept Protein Res. 1994 Mar;43(3):271-6 [7911792.001]
  • [Cites] Tumour Biol. 1995;16(4):261-7 [7604207.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):31-8 [8769376.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):98-100 [8769396.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12513-8 [8901613.001]
  • [Cites] Cell Signal. 1998 Apr;10(4):277-82 [9617485.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4C):3393-7 [10629625.001]
  • (PMID = 12556972.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 0 / TT2-32; 51110-01-1 / Somatostatin; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine
  • [Other-IDs] NLM/ PMC2376778
  •  go-up   go-down


6. Pham TH, Wolff B, Abraham SC, Drelichman E: Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience. Ann Surg Oncol; 2006 Mar;13(3):370-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience.
  • BACKGROUND: Goblet cell carcinoid (GCC) is a rare malignant tumor with distinct histological and clinical features.
  • Our goals were to review the surgical and chemotherapy outcomes of patients with GCC.
  • RESULTS: The age at diagnosis (mean +/- SE) was 55 +/- 13 years.
  • The corresponding survival rates for adjuvant chemotherapy versus no chemotherapy were 32% and 27%, respectively (P = .151).
  • CONCLUSIONS: The prognosis for patients with GCC tumors correlates well with the American Joint Committee on Cancer stage at initial presentation.
  • Adjuvant chemotherapy with 5-fluorouracil and leucovorin regimen is minimally effective against GCC.
  • [MeSH-major] Appendectomy. Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / surgery. Carcinoid Tumor / drug therapy. Carcinoid Tumor / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485156.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, Tillman RM: Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br; 2000 Jan;82(1):55-61
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience in the treatment of dedifferentiated chondrosarcoma.
  • Dedifferentiated chondrosarcoma is a rare, highly malignant variant of chondrosarcoma in which a high-grade spindle-cell sarcoma coexists with a lower-grade chondroid tumour.
  • We have reviewed our experience with this neoplasm in 22 patients, all of whom were treated using modern oncological principles of planned resection and chemotherapy.
  • Those patients who received chemotherapy, and in whom wide margins of excision were achieved at operation, did best.
  • It is essential to have an accurate preoperative diagnosis in order to plan treatment which may offer a better prospect of cure.
  • [MeSH-major] Bone Neoplasms / therapy. Chondrosarcoma / therapy

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10697315.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


8. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal metastases in malignant melanoma.
  • BACKGROUND: We present the case of a patient with malignant melanoma stage IV according to the American Joint Committee on Cancer (AJCC) classification and an unusual pattern of metastasis to the mucosa of the esophagus, the stomach, the bladder and the palatine tonsil.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • A few weeks later the patient developed macroscopic hematuria.
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed


9. Lachat MR, Weber M, Cserhati MD, Honegger HP, von Hochstetter AR: [Giant cell tumor of bone with rapid malignant course]. Orthopade; 2004 Mar;33(3):344-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of bone with rapid malignant course].
  • [Transliterated title] Riesenzelltumor des Knochens mit rapid malignem Verlauf.
  • The case of a 28-year-old male patient with a locally aggressive lesion of the distal tibia is presented.
  • Following the diagnosis of giant cell tumor of bone (GCT) on biopsy and curettage, a rapid malignant course was observed with recurrence 2.5 months later.
  • Following initial chemotherapy according to the COSS protocol and later with carboplatin and VP-16, therapy was changed to Adriamycin and later gemcitabine due to progressive disease.
  • The malignant nature of the tumor was not detected in the initial pathologic examinations.
  • Review of the pathologic material provided histologic clues permitting the diagnosis of a primary malignant GCT with a fibrohistiocytic/fibrosarcomatous component.
  • Malignancy in a giant cell tumor is a much debated diagnostic dilemma when a frank sarcomatous component is lacking.
  • Cytologic atypias and flame-like tufts of infiltration of soft tissue are important clues.
  • Surgical treatment should be commensurate.
  • [MeSH-major] Ankle Joint. Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Tibia
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Transplantation. Curettage. Disease Progression. Fatal Outcome. Humans. Lung / pathology. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):890-900 [4019539.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1244-55 [3855683.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):104-8 [11310196.001]
  • [Cites] J Bone Joint Surg Am. 1997 Feb;79(2):259-62 [9052550.001]
  • [Cites] Mod Pathol. 1989 Sep;2(5):541-6 [2554283.001]
  • [Cites] Cancer. 1979 Oct;44(4):1393-402 [227563.001]
  • [Cites] J Bone Joint Surg Am. 1992 Jul;74(6):930-4 [1634584.001]
  • [Cites] J Bone Joint Surg Am. 1989 Jun;71(5):757-61 [2732265.001]
  • [Cites] Clin Orthop Relat Res. 2000 Dec;(381):185-91 [11127655.001]
  • [Cites] J Bone Joint Surg Br. 1972 May;54(2):216-29 [5034822.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] AJR Am J Roentgenol. 1985 May;144(5):955-60 [3872579.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • (PMID = 15007559.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Potter BK, Adams SC, Qadir R, Pitcher JD, Temple HT: Fungating soft-tissue sarcomas. Treatment implications and prognostic importance of malignant ulceration. J Bone Joint Surg Am; 2009 Mar 1;91(3):567-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fungating soft-tissue sarcomas. Treatment implications and prognostic importance of malignant ulceration.
  • BACKGROUND: Several variables have been reported as being prognostic with regard to the outcomes of soft-tissue sarcomas.
  • Although the tumors are subjectively ominous, no prior study has been performed to evaluate the treatment or prognosis of fungating soft-tissue sarcomas.
  • METHODS: We performed a retrospective review of all soft-tissue sarcomas treated at our institution between 1989 and 2004 that had been followed for a minimum of two years or until the death of the patient.
  • Our study group consisted of twenty-four patients with a primary high-grade fungating tumor, and our control group consisted of 146 consecutive patients with a primary high-grade non-fungating tumor.
  • The study cohorts were compared with regard to disease presentation, treatment, and oncologic outcomes.
  • RESULTS: There were no significant differences in tumor size, tumor depth, or histopathologic diagnoses between the cohorts, although the patients with a fungating tumor tended to be older (mean, sixty-five years compared with fifty-five years in the control group; p = 0.004) and have shorter postoperative follow-up (mean, thirty-eight months compared with sixty-five months in the control group; p = 0.03).
  • The proportion of patients presenting with metastases was significantly greater in the group with a fungating tumor (33% compared with 9% in the control group; p = 0.003).
  • Significantly more patients with a fungating tumor underwent amputation (35% compared with 12% in the control group; p = 0.01), while a greater proportion of control patients received radiation therapy (68% compared with 39% in the group with a fungating tumor; p = 0.02).
  • There was no difference in the proportions of patients receiving chemotherapy or in the local recurrence rates between the two cohorts.
  • The Kaplan-Meier five-year overall survival estimates were 20% in the group with a fungating tumor compared with 63% (p < 0.0001) in the control group.
  • The Kaplan-Meier five-year disease-specific survival estimates for patients presenting with localized disease was 58% in the group with a fungating tumor and 74% in the control group (p = 0.05).
  • Multivariate analysis demonstrated that disease stage, fungation, and a tumor size of > or = 10 cm were significant independent negative prognostic factors for disease-specific survival.
  • CONCLUSIONS: Malignant tumor ulceration is an independent predictor of a poor prognosis for patients with a high-grade soft-tissue sarcoma.
  • Despite the discouraging overall prognosis, aggressive multidisciplinary treatment can lead to long-term survival in an important subgroup of patients with fungating lesions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19255216.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kavanagh D, Hill AD, Djikstra B, Kennelly R, McDermott EM, O'Higgins NJ: Adjuvant therapies in the treatment of stage II and III malignant melanoma. Surgeon; 2005 Aug;3(4):245-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapies in the treatment of stage II and III malignant melanoma.
  • Despite these improvements, 5-year survival rates for American Joint Committee on Cancer stage II and III disease range from 50%-90%.
  • METHODS: A review of the current literature concerning adjuvant therapies in patients with stage II and III malignant melanomas was undertaken.
  • RESULTS: The focus of adjuvant therapies has shifted from radiotherapy, BCG and levamisole to newer biological agents.
  • CONCLUSION: At present, no adjuvant therapy improves overall survival in patients with stage II and III melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Humans. Immunotherapy. Immunotherapy, Active. Interleukin-2 / therapeutic use. Neoplasm Staging. Radiotherapy, Adjuvant. Surgical Procedures, Operative

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121769.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  • [Number-of-references] 89
  •  go-up   go-down


12. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR: Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg; 2007 Nov;84(5):1685-92; discussion 1692-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma is a locally aggressive tumor that is usually fatal.
  • To improve local control, we have used intensity-modulated radiation therapy (IMRT) as it allows better dose distribution to regions at risk of recurrence as well as reduced radiation to surrounding organs.
  • At a median interval of 2.5 months from surgery, 63 patients received IMRT (median dose 45 Gy) with curative intent.
  • Chemotherapy was not routinely administered.
  • American Joint Committee on Cancer pathology stage was I in 6 patients (6%), II in 7 (7%), III in 72 (72%), and IV (T4) in 15 (15%).
  • CONCLUSIONS: Intensity-modulated radiation therapy after EPP results in excellent local control for malignant pleural mesothelioma; however, distant metastases remain a significant problem and limit survival.
  • This provides a strong rationale for combining aggressive local regimens with systemic therapy.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Pneumonectomy / methods. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications / epidemiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954086.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


13. Fu M, Shen JN, Huang G, Wang J, Fu QZ, Yang ZH: [Reconstruction of the hemipelvis with saddle prosthesis after excision of malignant tumors around the pelvis and acetabulum: a report of 12 cases]. Ai Zheng; 2007 Nov;26(11):1237-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction of the hemipelvis with saddle prosthesis after excision of malignant tumors around the pelvis and acetabulum: a report of 12 cases].
  • BACKGROUND & OBJECTIVE: Malignant tumors around the pelvis and acetabulum locate deeply with complex anatomic structure, meanwhile, the resection area involves the weight-loading alignment.
  • Therefore, tumor resection plus acetabular joint reconstruction is a complicated operation.
  • This study was to summarize our experience of tumor resection plus prosthesis reconstruction of the acetabular joint for this disease.
  • METHODS: Clinical data of 12 patients with malignant tumors around the pelvis and acetabulum, treated with tumor resection plus prosthesis reconstruction of the acetabular joint from 1995 to 2006, were reviewed.
  • The characteristics of the operating for this disease were analyzed in terms of preoperative preparation, operating strategy, prosthesis design, operating procedure, acetabular reconstruction, and postoperative rehabilitation.
  • Of the 4 patients with tumor relapse, 2 osteosarcoma patients died of lung metastasis at 15 months and 22 months after operation; 1 chondrosarcoma patient relapsed locally at 26 months after operation and died at 38 months after operation; 1 giant cell tumor patient relapsed locally at 13 months after operation and was treated by clearance of focal lesion, and survived tumor-freely till the end of follow-up.
  • The other 9 patients still survived tumor-freely till the end of follow-up.
  • CONCLUSIONS: Pelvic tumor resection and prosthesis reconstruction of the acetabular joint has the characteristics of difficulty and high-risk.
  • For bone tumors with relatively low malignancy, this surgical treatment is an ideal option.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Osteosarcoma / drug therapy. Osteosarcoma / secondary. Osteosarcoma / surgery. Pelvic Bones / surgery. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


14. Lawson DH: Update on the systemic treatment of malignant melanoma. Semin Oncol; 2004 Apr;31(2 Suppl 4):33-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the systemic treatment of malignant melanoma.
  • The purpose of this article is to review some of the recent advances and disappointments in the systemic treatment of melanoma and to highlight some of the ongoing trials in this area.
  • Two major advances in the staging of melanoma are the new American Joint Committee on Cancer staging system and the use of the sentinel node biopsy.
  • Interferon remains the standard adjuvant therapy for high-risk patients.
  • Dacarbazine and high-dose IL-2 are the only US Food and Drug Administration approved systemic treatments for stage IV disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cancer Vaccines / therapeutic use. Melanoma / therapy
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15124132.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines
  • [Number-of-references] 43
  •  go-up   go-down


15. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF: Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol; 2008 Oct;15(10):2749-56
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb infusion for advanced soft tissue sarcoma of the extremity.
  • BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive technique for delivering high-dose regional chemotherapy.
  • We report our experience with ILI for the treatment of soft tissue sarcoma (STS).
  • In all patients, a high-dose cytotoxic drug combination was used.
  • The procedure was well tolerated.
  • Fourteen patients (67%) received ILI before definitive surgery.
  • Only American Joint Committee on Cancer stage was associated with overall survival.
  • CR and malignant fibrous histiocytoma tumor subtype were associated with a lower local recurrence rate.
  • Patients who had a steep increase in intramuscular temperature during the procedure were more likely to have a CR (P = .055).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / pathology. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Dactinomycin / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648882.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; Q41OR9510P / Melphalan
  •  go-up   go-down


16. Kenan S, Ginat DT, Steiner GC: Dedifferentiated high-grade osteosarcoma originating from low-grade central osteosarcoma of the fibula. Skeletal Radiol; 2007 Apr;36(4):347-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low grade central osteosarcoma is a distinct, rare low grade malignant neoplasm characterized histologically by a spindle cell proliferation associated with trabecular bone formation.
  • This tumor usually carries a good prognosis.
  • However, it has the potential to recur, dedifferentiate, and metastasize subsequent to surgical treatment.
  • Following biopsy the patient received 3 months of chemotherapy at a different institution.
  • X-rays indicated a very aggressive tumor in the diaphysis of the proximal fibula, MRI revealed soft tissue involvement.
  • The tumor and surrounding soft-tissues were excised en bloc at our institution.
  • The two histological components of the tumor were sharply delineated from one another.
  • No chemotherapy effect was appreciated histologically or clinically.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fibula / pathology. Lung Neoplasms / secondary. Osteosarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging / methods


17. Saifuddin A: The accuracy of imaging in the local staging of appendicular osteosarcoma. Skeletal Radiol; 2002 Apr;31(4):191-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Appendicular osteosarcoma represents the commonest malignant bone tumour for which limb salvage surgery and endoprosthetic replacement is performed.
  • These techniques have been made possible due to the introduction of effective neoadjuvant chemotherapy and demand a high degree of accuracy in the assessment of local staging.
  • Extramedullary extension includes an assessment of joint involvement, relationship to the neurovascular bundle and involvement of muscle compartments.
  • These factors will determine the feasibility and type of limb salvage performed.
  • [MeSH-major] Bone Neoplasms / diagnosis. Neoplasm Staging / methods. Osteosarcoma / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11904686.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


18. Weisskopf M, Münker R, Hermanns-Sachweh B, Ohnsorge JA, Siebert C: Epithelioid sarcoma in the thoracic spine. Eur Spine J; 2006 Oct;15 Suppl 5:604-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelioid sarcoma is a rare and highly malignant soft tissue tumor that is commonly found in the extremities and rarely in the trunk area.
  • This malignant tumor often mimics granuloma or nodular fasciitis, which causes a delay in establishing the diagnosis.
  • This type of cancer has a high recurrence rate.
  • Surgical treatment requires wide radical resection.
  • The objective of this case report is to highlight the unique location of a rare neoplasm and to illustrate the relentless course of epithelioid sarcoma despite initial radical resection.
  • A 14-year-old boy was admitted to our facility with a soft tissue mass on the right lower thoracic spine.
  • The large tumor mass had deeply penetrated into the muscles, infiltrated the neuroforamen of T9-T10 level, and compressed the dural sac.
  • The patient received chemotherapy and irradiation.
  • The first recurrence of the neoplasm was seen as a contralateral metastasis 21 months after the resection.
  • Initial wide excision of the neoplasm and adjuvant therapy including chemotherapy and irradiation seem to slow down the relentless course of epithelioid sarcoma in the trunk.
  • [MeSH-major] Orthopedic Procedures. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Spinal Neoplasms / diagnosis. Thoracic Vertebrae
  • [MeSH-minor] Adolescent. Biopsy. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Orthopedic Fixation Devices. Positron-Emission Tomography. Postoperative Period. Radiography, Thoracic. Spinal Fusion

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Orthop. 2002;26(1):26-30 [11954844.001]
  • [Cites] Radiology. 2004 Mar;230(3):697-702 [14749514.001]
  • [Cites] Cancer. 1970 Nov;26(5):1029-41 [5476785.001]
  • [Cites] Pol Med J. 1971;10(1):12-7 [5573897.001]
  • [Cites] Cancer. 1972 Jul;30(1):128-43 [4339255.001]
  • [Cites] Cancer. 1972 Aug;30(2):486-99 [4340662.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):491-5 [9309338.001]
  • [Cites] Cancer. 1978 Apr;41(4):1472-87 [639005.001]
  • [Cites] Am J Surg Pathol. 1985 Apr;9(4):241-63 [4014539.001]
  • [Cites] J Bone Joint Surg Am. 1988 Jul;70(6):862-70 [3392084.001]
  • [Cites] Eur J Surg Oncol. 1989 Aug;15(4):345-9 [2759252.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1189-91 [7807342.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Mar 1;21(5):634-8 [8852321.001]
  • [Cites] Cancer. 1977 Jan;39(1):143-52 [188535.001]
  • (PMID = 16474944.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC1602205
  •  go-up   go-down


19. Punt SE, Eary JF, O'Sullivan J, Conrad EU: Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics. Nucl Med Commun; 2009 Jul;30(7):546-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics.
  • OBJECTIVE: Leiomyosarcoma, a malignant neoplasm of smooth muscle, accounts for 7% of the sarcomas.
  • These tumors, which are derived from mesenchymal tissues, are difficult to diagnose, and treatment options remain controversial.
  • The relatively rare incidence of this soft tissue sarcoma subtype has limited the number of patients available for studies and research.
  • This study examines whether the imaging characteristics of positron emission tomography (PET) with radiolabeled fluorodeoxyglucose (FDG) provide a reliable, noninvasive means to predict tumor behavior in patients with leiomyosarcomas.
  • METHODS: [18F]-FDG-PET was performed on the tumors of participating patients before the neoadjuvant chemotherapy or resection, and a maximum tumor standard uptake value (SUVmax) was calculated.
  • RESULTS: The SUVmax was correlated with tumor grade (P=0.001) and tumor size as greatest dimension (P=0.004).
  • Analysis of these data indicated the potential effectiveness of FDG-PET imaging in predicting tumor grade.
  • CONCLUSION: In leiomyosarcoma, the SUVmax from FDG-PET is a likely predictor of tumor behavior.
  • The results of this study suggest that a large (by greatest dimension) intermediate grade tumor is expected to have the same predicted outcome as a high-grade tumor and should be treated in the same manner, as they share the same prognosis by definition of tumor grade.
  • Improvements made in the clinical treatment of leiomyosarcomas by use of FDG-PET imaging data may lead to an increase in patient survival.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004;86-A Suppl 2:98-104 [15691114.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8828-34 [16314643.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1215-20 [9607579.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):500-5 [10749609.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1279-87 [10778952.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Skeletal Radiol. 2001 Oct;30(10):543-59 [11685477.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1149-54 [12192559.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):930-42 [12791822.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):701-4 [14766270.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):189-95 [15129700.001]
  • [Cites] Ir J Med Sci. 2011 Dec;180(4):889-91 [19184604.001]
  • [Cites] Clin Orthop Relat Res. 2009 Jun;467(6):1605-11 [19048352.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(17-18):557-60 [17943409.001]
  • [Cites] Ann Thorac Surg. 2007 May;83(5):1826-9; discussion 1829-30 [17462407.001]
  • [Cites] Kyobu Geka. 2006 Dec;59(13):1191-6 [17163213.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1290-5 [16832631.001]
  • (PMID = 19440162.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA065537-13; United States / NCI NIH HHS / CA / R01 CA065537; United States / NCI NIH HHS / CA / R01 CA 65537; United States / NCI NIH HHS / CA / R01 CA065537-13
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS121746; NLM/ PMC2752415
  •  go-up   go-down


20. Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis; 2007;2:6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteosarcoma is a primary malignant tumour of the skeleton characterised by the direct formation of immature bone or osteoid tissue by the tumour cells.
  • The classic osteosarcoma is a rare (0.2% of all malignant tumours) highly malignant tumour, with an estimated incidence of 3 cases/million population/year.
  • Osteosarcoma arises predominantly in the long bones and rarely in the soft tissues.
  • Plain radiographs, computed tomography, magnetic resonance imaging, angiography and dynamic bone scintigraphy are used for diagnosis, evaluation the extent of tumour involvement and decision of the type of operation and, if necessary, the type of reconstruction.
  • Years ago, all patients with osteosarcoma were treated by amputation but the cure rate was under 10% and almost all patients died within a year from diagnosis.
  • Today, for localised osteosarcoma at onset (80% of cases) treated in specialized bone tumour centres with pre- and postoperative chemotherapy associated with surgery, the percentage of patients cured varies between 60% and 70%.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / therapy. Osteosarcoma / diagnosis. Osteosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Diagnosis, Differential. Female. Humans. Incidence. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Bone Tissue / diagnosis. Prognosis. Sex Distribution

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2002 Apr;84(3):395-400 [12002500.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1126-34 [12853357.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4016-27 [11118462.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):39-46 [11165128.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):171-5 [11748477.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1601-4 [11822761.001]
  • [Cites] J Bone Joint Surg Br. 2002 Jan;84(1):88-92 [11837839.001]
  • [Cites] Clin Orthop Relat Res. 1973 Nov-Dec;(97):64-8 [4521231.001]
  • [Cites] Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976 May-Jun;81(3 Pt 1):454-7 [1066869.001]
  • [Cites] Recent Results Cancer Res. 1976;(54):92-103 [189372.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):5-15 [1370176.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):925-30 [8164043.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1208-14 [7850721.001]
  • [Cites] Orthop Clin North Am. 1996 Jul;27(3):473-81 [8649730.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2011-8 [12743156.001]
  • (PMID = 17244349.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  • [Other-IDs] NLM/ PMC1794406
  •  go-up   go-down


21. Mitsuhashi A, Nagai Y, Suzuka K, Yamazawa K, Nojima T, Nikaido T, Ishikura H, Matsui H, Shozu M: Primary synovial sarcoma in fallopian tube: case report and literature review. Int J Gynecol Pathol; 2007 Jan;26(1):34-7
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synovial sarcoma, a malignant mesenchymal neoplasm, occurs mostly near the joints of the extremities and occasionally outside the joint such as lung.
  • We report a case of soft tissue sarcoma arising in the fallopian tube origin that showed characteristic pathological appearance of biphasic synovial sarcoma.
  • Molecular analysis detected a fusion gene transcript of synovial sarcoma translocation (SYT) gene from chromosome 18 and synovial sarcoma X chromosome breakpoint 1 (SSX1) gene, which is believed to pathognomonic for synovial sarcoma of joint origin.
  • Recurrent abdominal tumor, observed at 12 month after the initial surgery and following chemotherapy using doxorubicin, cisplatin and ifosfamide, partially responded to chemotherapy using paclitaxel and carboplatin and, then, optimal surgery was performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197895.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  • [Number-of-references] 12
  •  go-up   go-down


22. Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B, Price GS, Thrall DE: A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound; 2003 May-Jun;44(3):352-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the early notion that canine oral malignant melanoma is radioresistant, recent data suggest that external beam radiotherapy is effective in local tumor control.
  • The role of chemotherapy in the management of canine oral melanoma has also not been determined.
  • (1) to compare the efficacy of three radiation therapy protocols (36 Gy, 9 Gy x 4 fractions; 30 Gy, 10 Gy x 3 fractions; or >45 Gy, 2-4 Gy x 12-19 fractions) for the treatment of dogs with oral malignant melanoma, (2) to identify any host or tumor factors influencing prognosis, and (3) to determine the impact of systemic chemotherapy on treatment outcome.
  • Information regarding response to therapy, disease progression, and survival were determined from the medical records or from information obtained by telephone or mail survey.
  • Relationships between host, tumor, and treatment variables and outcome measures (response, time to first event, and survival) were evaluated using Fisher's exact test (response) and the Cox regression model (time to first event and survival).
  • The median time to first event for the 140 dogs was 5.0 months (95% C.I., 4-6 months) and the median survival was 7.0 months (95% C.I., 6-9 months).
  • In the univariate analysis, the following variables were associated with increased time to first event and survival:.
  • (1) rostral tumor sublocation;.
  • (2) lack of bone lysis observed on skull imaging, and (3) microscopic tumor burden.
  • In a multivariate analysis of 111 dogs with complete data for these variables, tumor sublocation, bone lysis, and tumor volume were identified as joint predictors of time to first event (p < .001, p < .001, and p = .04, respectively) and survival (p < .001, p < .001, and p = .05, respectively).
  • There were no differences in response, time to first event and survival between the three radiation therapy protocols used.
  • Systemic chemotherapy had no impact on the development of metastatic disease, time to first event, or survival, although the dosages used in this study were suboptimal.
  • External beam radiation therapy is effective in local disease control of canine oral malignant melanoma; however, the optimal fractionation scheme has yet to be determined.
  • The high metastatic rate observed with this disease and the inefficacy of systemic chemotherapy indicate that further investigation into novel therapies is warranted.
  • [MeSH-major] Dog Diseases / mortality. Melanoma / veterinary. Mouth Neoplasms / veterinary. Neoplasm Recurrence, Local / veterinary
  • [MeSH-minor] Animals. Disease-Free Survival. Dogs. Dose Fractionation. Female. Male. North Carolina / epidemiology. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12816381.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Wang W, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer; 2010 Nov;29(11):923-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The American Joint Committee on Cancer / International Union against Cancer (AJCC/UICC) published the TNM classification of Malignant Tumors (seventh edition) for gastric cancer recently.
  • In both univariate analysis and Cox multivariate analysis, age, tumor site, tumor size, histological type, resection type, radical resection, lymphatic/venous invasion, depth of invasion, nodal status, metastasis, retrieved lymph nodes, metastatic lymph node ratio, and adjuvant chemotherapy were prognostic factors with these patients.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Neoplasm Staging / standards. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979691.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Gruner U, Goesch P, Donner A, Peters U: [Whipple disease and non-Hodgkin lymphoma]. Z Gastroenterol; 2001 Apr;39(4):305-9
Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some years before he had developed joint pain, symmetric at both hands and feet.
  • Treatment with Co-trimoxazole for more than 21 months achieved remission.
  • 6 years after diagnosis of Whipple's disease the patient presented with multilocal lymphadenopathy.
  • Malignant Non-Hodgkin-Lymphoma (Centrocytom) stage PS IV b was diagnosed.
  • COP-chemotherapy (Vincristine, Cyclophosphamide, Prednisone) achieved partial remission up to now.
  • Whether the appearance of the malignant lymphoma is a consequence of Whipple's disease or a second neoplastic disease remains to be answered by further epidemiological studies.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Remission Induction. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Whipple disease.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11367979.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination
  •  go-up   go-down


25. Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR: The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS One; 2008;3(12):e3940
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
  • Loss of the PTEN tumor suppressor is a common occurrence in human prostate cancer, particularly in advanced disease.
  • Given that the prostate undergoes rapid androgen-dependent growth at puberty, and that Pten excisions during this time might be especially tumorigenic, we hypothesized that delaying prostate-specific Pten deletions until immediately after puberty might alter the pace of tumorigenesis.
  • Despite evidence of increased Akt/mTOR/S6K axis activity at early time points in Pten-deficient epithelial cells, excisions induced in the post-pubertal (6 wk-old) prostate yielded gradual acquisition of a range of lesions.
  • These progressed from pre-malignant changes (nuclear atypia, focal hyperplasia) and low grade prostatic intraepithelial neoplasia (PIN) at 16-20 wks post-tamoxifen exposure, to overtly malignant lesions by approximately 1 yr of age, characterized by high-grade PIN and microinvasive carcinoma.
  • In contrast, when Pten excisions were triggered in the pre-pubertal (2 week-old) prostate, neoplasia evolved over a more abbreviated time-frame, with a spectrum of premalignant lesions, as well as overt PIN and microinvasive carcinoma by 10-12 wks post-tamoxifen exposure.
  • [MeSH-major] Gene Deletion. Genes, Tumor Suppressor. PTEN Phosphohydrolase / genetics. Prostatic Intraepithelial Neoplasia / enzymology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / enzymology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Androgen-Binding Protein / genetics. Animals. Apoptosis. Arrestins / metabolism. Cell Proliferation. Crosses, Genetic. Disease Progression. Epithelium / enzymology. Epithelium / pathology. Female. Humans. Integrases / metabolism. Male. Mice. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. Precancerous Conditions / drug therapy. Precancerous Conditions / enzymology. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Rats. Ribosomal Protein S6 / metabolism. Tamoxifen / analogs & derivatives. Tamoxifen / therapeutic use. Time Factors. Up-Regulation

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Sep;4(3):209-21 [14522255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] J Biol Chem. 1994 Dec 16;269(50):31763-9 [7989349.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Prostate. 1997 Jul 1;32(2):129-39 [9215401.001]
  • [Cites] J Androl. 1999 Mar-Apr;20(2):251-8 [10232660.001]
  • [Cites] J Mol Endocrinol. 1999 Jun;22(3):313-25 [10343290.001]
  • [Cites] Development. 1999 Aug;126(16):3693-701 [10409514.001]
  • [Cites] J Cell Biochem. 2005 Feb 1;94(2):279-97 [15565647.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):673-84 [15976331.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5730-9 [15994948.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):725-30 [16079851.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):184-96 [16412571.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5305-11 [17000663.001]
  • [Cites] Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62 [17052169.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Annu Rev Pathol. 2006;1:243-71 [18039115.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):572-85 [18068633.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2521-6 [18268330.001]
  • [Cites] Genesis. 2008 Apr;46(4):229-34 [18395839.001]
  • [Cites] Cell. 2008 May 2;133(3):403-14 [18455982.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Genesis. 2000 Feb;26(2):154-6 [10686616.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4698-710 [11108285.001]
  • [Cites] Mech Dev. 2001 Mar;101(1-2):61-9 [11231059.001]
  • [Cites] Trends Genet. 2002 May;18(5):S1-5 [12047956.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1725-30 [14747659.001]
  • (PMID = 19081794.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen-Binding Protein; 0 / Arrestins; 0 / Ribosomal Protein S6; 0 / beta-arrestin; 094ZI81Y45 / Tamoxifen; 17197F0KYM / afimoxifene; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2597775
  •  go-up   go-down


26. Willmott F, Agarwal N, Heath M, Stevens J, Chakravarti S: Plasma cell myeloma diagnosed in pregnancy. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical picture is one of bone marrow failure, due to infiltration of the marrow by malignant plasma cells; renal failure due to damage to renal tubules by the excess light chains and pain due to lytic lesions of the bones.
  • [MeSH-major] Multiple Myeloma / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow / pathology. Cesarean Section. Disease Progression. Female. Fetal Growth Retardation / diagnosis. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Male. Neoplasm Staging. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / drug therapy. Puerperal Disorders / pathology. Remission Induction

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004 Jun;86-A(6):1284-8 [15173303.001]
  • [Cites] Blood. 1966 Jul;28(1):102-11 [5944257.001]
  • [Cites] Obstet Gynecol. 1968 Jun;31(6):811-20 [5742077.001]
  • [Cites] West Indian Med J. 1971 Jun;20(2):97-100 [5110487.001]
  • [Cites] Cancer. 1974 Oct;34(4):1018-22 [4417641.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):38-42 [3800603.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):513-5 [2304725.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):516-8 [2304726.001]
  • [Cites] Int J Gynaecol Obstet. 1991 Aug;35(4):341-2 [1682183.001]
  • [Cites] Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):217-9 [7847542.001]
  • [Cites] Leuk Res. 1997 Sep;21(9):885-8 [9393604.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):108-12 [15923168.001]
  • [Cites] J Obstet Gynaecol. 2006 Oct;26(7):693-5 [17071446.001]
  • [Cites] Nephrol Dial Transplant. 2007 Dec;22(12):3652-5 [17875572.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Jan;100(1):89-90 [17825829.001]
  • [Cites] Ann Hematol. 2009 Feb;88(2):181-2 [18682949.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):214-5 [14597255.001]
  • (PMID = 22791481.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027817
  •  go-up   go-down


27. Dumont FJ: Alemtuzumab (Millennium/ILEX). Curr Opin Investig Drugs; 2001 Jan;2(1):139-60
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alemtuzumab, a lymphocyte-depleting humanized monoclonal antibody, is being developed by Millennium Pharmaceuticals Inc and ILEX Oncology for the potential treatment of chronic lymphocytic leukemia (CLL) [274580].
  • The utility of the compound for treating bone marrow (BM) stem cell transplantation-associated graft-versus-host disease (GVHD) [372946] and for ex vivo purging of BM to remove malignant T-cells [244056] is also being investigated.
  • Additional potential therapeutic areas for which clinical trials are planned or ongoing include vasculitis, multiple sclerosis [288762] and organ transplantation [338304].
  • Alemtuzumab has received Fast Track designation [304771] and orphan drug status from the FDA [288762], and the drug was reviewed by the FDA's Oncologic Drugs Advisory Committee on 14 December, 2000 [387228].
  • The committee voted 14 to 1 to recommend accelerated approval of alemtuzumab for patients with CLL who have been treated with alkylating agents and who have failed fludarabine therapy [393778], [393894].
  • In October 2000, EMEA accepted the MAA for alemtuzumab under the agency's centralized approval procedure [387228].
  • In April 1997, LeukoSite licensed rights to the antibody from BTG for the treatment of CLL and prolymphocytic leukemia, plus an option to develop it for other indications.
  • In May 1997, LeukoSite entered into a joint venture with ILEX Oncology for the further development of alemtuzumab [245986].
  • By the end of 1999, Millennium acquired LeukoSite with commitment to pursue development of the compound through the joint venture Millennium & ILEX Partners LP [351523], [370237].
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Immunosuppressive Agents / therapeutic use
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Arthritis, Rheumatoid / drug therapy. Clinical Trials as Topic. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Multiple Sclerosis / drug therapy. Organ Transplantation. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11527007.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down






Advertisement